However, a comprehensive analysis across nine cancer types revealed no correlation between the baseline IRF9 expression and cisplatin sensitivity, but an increase in IRF9 expression following DNA-damaging chemotherapy correlated with drug responsiveness. Here, IRF9 is linked to cancer.